Dare Bioscience, Inc.
DARE
NASDAQ·Healthcare·Biotechnology·Mkt cap $12.6M
$0.85
▼ -0.27%
P/E
-1.08
Mkt Cap
$12.6M
52-Wk Range
$0.69–$3.78
52-Week Range
$0.69 - $3.78
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 62.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage in innovative vaginal delivery platforms and formulations
- Focused expertise in underserved women's health market with diversified pipeline
- Strategic partnerships with major pharmaceutical companies (Organon & Co.)
- Proprietary intravaginal ring technology for sustained hormone and drug delivery
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
XACIATO commercialization revenue and market penetration expansion
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-59.5% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying DARE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.20 vs -$0.30 consensus (+32.6% surprise). Revenue of $187.5K vs $1.7K expected (+11150.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+32.6%
Revenue trend · last 8Q
—
—
+173%
-194%
-95%
—
+500%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$41.7K
-$63.6K
$25.4K
-$21.2K
$2.3K
$1.0M
$152.5K
$187.5K
Margins · last 8Q
Gross
-70.6%
Operating
—
Profit
-1590.4%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How DARE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related